Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | CCR2 | P41597 | 6/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21647472 | 0.91 | KDM4E (0.51) | ALDH1A1KDM4EHPGDHSD17B10CCR2 | |
| SCHEMBL21647590 | 0.89 | CCR2 (0.54) | ALDH1A1KDM4EHPGDHSD17B10CCR2 | |
| SCHEMBL30547765 | 0.85 | CCR2 (0.53) | ALDH1A1KDM4EHPGDHSD17B10CCR2 | |
| SCHEMBL30547789 | 0.85 | MEN1 (0.47) | ALDH1A1KDM4EHPGDHSD17B10CCR2 | |
| SCHEMBL21647437 | 0.85 | KDM4E (0.49) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL12466547 | 0.85 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDHSD17B10CCR2 | |
| SCHEMBL21647544 | 0.83 | GPR35 (0.46) | ALDH1A1KDM4EHPGDHSD17B10CCR2 | |
| SCHEMBL12466305 | 0.82 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10CCR2 | |
| SCHEMBL3114034 | 0.82 | CCR2 (0.53) | ALDH1A1KDM4EHPGDHSD17B10CCR2 | |
| SCHEMBL29750342 | 0.82 | ALDH1A1 (0.64) | ALDH1A1KDM4ECCR2SMN1; SMN2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202829-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-11639354-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2021-06-17 | — | — | US | disclosed |
| EP-3831811-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2021-06-09 | — | — | EP | disclosed |
| CN-112533898-A | Heterocyclic compounds | 日商泛美克斯股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2020027225-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | ALDH1A1 2510/4885KDM4E 2577/4885HPGD 947/4885 |
| US-11639354-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | ALDH1A1 2510/4885KDM4E 2577/4885HPGD 947/4885 |
| US-12202829-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | ALDH1A1 2510/4885KDM4E 2577/4885HPGD 947/4885 |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | ALDH1A1 2510/4885KDM4E 2577/4885HPGD 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.